Should I buy or sell Qiagen stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Qiagen in the last twelve months. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" QGEN shares. View QGEN analyst ratings or view top-rated stocks .

What is Qiagen's stock price target for 2024?

8 brokerages have issued 12 month price objectives for Qiagen's shares. Their QGEN share price targets range from $43.30 to $60.00. On average, they anticipate the company's stock price to reach $51.79 in the next year. This suggests a possible upside of 16.4% from the stock's current price. View analysts price targets for QGEN or view top-rated stocks among Wall Street analysts .

How have QGEN shares performed in 2024?

Qiagen's stock was trading at $44.7732 at the beginning of the year. Since then, QGEN stock has decreased by 0.6% and is now trading at $44.49. View the best growth stocks for 2024 here .

Are investors shorting Qiagen?

Qiagen saw a increase in short interest in the month of January. As of January 15th, there was short interest totaling 3,120,000 shares, an increase of 28.9% from the December 31st total of 2,420,000 shares. Based on an average daily trading volume, of 1,370,000 shares, the days-to-cover ratio is presently 2.3 days. Approximately 1.4% of the company's shares are sold short. View Qiagen's Short Interest .

When is Qiagen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our QGEN earnings forecast .

How were Qiagen's earnings last quarter?

Qiagen (NYSE:QGEN) released its quarterly earnings results on Tuesday, February, 6th. The company reported $0.55 earnings per share for the quarter, hitting the consensus estimate of $0.55. The firm had revenue of $509 million for the quarter, compared to analyst estimates of $500.77 million. Qiagen had a net margin of 17.37% and a trailing twelve-month return on equity of 12.99%. During the same period in the prior year, the company earned $0.53 EPS.

How often does Qiagen pay dividends? What is the dividend yield for Qiagen?

Qiagen announced a -- dividend on Monday, January 22nd. Investors of record on Wednesday, January 31st will be paid a dividend of $1.3196 per share on Tuesday, January 30th. The ex-dividend date of this dividend is Tuesday, January 30th. Read our dividend analysis for QGEN .

What ETFs hold Qiagen's stock?

ETFs with the largest weight of Qiagen (NYSE:QGEN) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM) , First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) , First Trust NYSE Arca Biotechnology Index Fund (FBT) , Newday Ocean Health ETF (AHOY) , VanEck Biotech ETF (BBH) , Franklin Genomic Advancements ETF (HELX) , WisdomTree U.S. AI Enhanced Value Fund (AIVL) and ROBO Global Healthcare Technology and Innovation ETF (HTEC) .

When did Qiagen's stock split?

Qiagen's stock reverse split on Tuesday, January 30th 2024. The 24.25-25 reverse split was announced on Tuesday, January 30th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 30th 2024. An investor that had 100 shares of stock prior to the reverse split would have 97 shares after the split.

What guidance has Qiagen issued on next quarter's earnings?

Qiagen updated its FY 2024 earnings guidance on Tuesday, February, 6th. The company provided earnings per share (EPS) guidance of 2.100- for the period, compared to the consensus EPS estimate of 2.100. The company issued revenue guidance of $2.0 billion-, compared to the consensus revenue estimate of $2.1 billion.

What is Thierry Bernard's approval rating as Qiagen's CEO?

33 employees have rated Qiagen Chief Executive Officer Thierry Bernard on Glassdoor.com . Thierry Bernard has an approval rating of 65% among the company's employees.

What other stocks do shareholders of Qiagen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Qiagen investors own include NVIDIA (NVDA) , QUALCOMM (QCOM) , Gilead Sciences (GILD) , Advanced Micro Devices (AMD) , PayPal (PYPL) , Netflix (NFLX) , Pfizer (PFE) , Cisco Systems (CSCO) , Amgen (AMGN) and Lam Research (LRCX) .

Who are Qiagen's major shareholders?

Qiagen's stock is owned by many different institutional and retail investors. Top institutional shareholders include Massachusetts Financial Services Co. MA (10.88%), Norges Bank (2.75%), DekaBank Deutsche Girozentrale (1.41%), BNP Paribas Financial Markets (0.69%), Neuberger Berman Group LLC (0.65%) and Allspring Global Investments Holdings LLC (0.59%).

How do I buy shares of Qiagen?

Shares of QGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSE:QGEN

Qiagen (QGEN) Stock Price, News & Analysis

$44.49

+0.37 (+0.84%)

(As of 02/9/2024 08:56 PM ET)

Compare

Today's Range: $43.70
▼
$44.49
50-Day Range: $42.18
▼
$46.65
52-Week Range: $34.74
▼
$49.26

Volume: 1.17 million shs
Average Volume: 1.68 million shs
Market Capitalization: $9.84 billion

P/E Ratio: 29.41
Dividend Yield: N/A
Price Target: $51.79

Get Qiagen alerts:

Qiagen MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.63 Rating Score
Upside/Downside: 16.4% Upside
$51.79 Price Target
Short Interest: Healthy
1.37% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.83
Upright™ Environmental Score
News Sentiment: 0.37
Based on 28 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 10.00%
From $2.10 to $2.31 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.59 out of 5 stars

Medical Sector

75th out of 922 stocks

Biological Products, Except Diagnostic Industry

12th out of 154 stocks

3.3

Analyst's Opinion

Consensus Rating
Qiagen has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on 5 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $51.79, Qiagen has a forecasted upside of 16.4% from its current price of $44.49.
Amount of Analyst Coverage
Qiagen has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
1.37% of the float of Qiagen has been sold short.
Short Interest Ratio / Days to Cover
Qiagen has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Qiagen has recently increased by 28.93%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Qiagen does not currently pay a dividend.
Dividend Growth
Qiagen does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Qiagen has received a 69.71% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Pharmacovigilance services", "Clinical research services", and "Biochemical assay kits" products. See details.
Environmental Sustainability
The Environmental Impact score for Qiagen is -0.83.

2.4

News and Social Media Coverage

News Sentiment
Qiagen has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.92 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 28 news articles for Qiagen this week, compared to 5 articles on an average week.
MarketBeat Follows
5 people have added Qiagen to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Qiagen insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 9.00% of the stock of Qiagen is held by insiders.
Percentage Held by Institutions
57.99% of the stock of Qiagen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

2.5

Earnings and Valuation

Earnings Growth
Earnings for Qiagen are expected to grow by 10.00% in the coming year, from $2.10 to $2.31 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Qiagen is 29.41, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 117.61.
Price to Earnings Ratio vs. Sector
The P/E ratio of Qiagen is 29.41, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 89.11.
Price to Earnings Growth Ratio
Qiagen has a PEG Ratio of 16.34. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Qiagen has a P/B Ratio of 2.58. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Qiagen Stock (NYSE:QGEN)

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

QGEN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

QGEN Stock News Headlines

February 11, 2024 | seekingalpha.com

Qiagen N.V. 2023 Q4 - Results - Earnings Call Presentation

February 11, 2024 | americanbankingnews.com

Qiagen (NYSE:QGEN) Price Target Raised to $52.00

February 12, 2024 | The Freeport Society (Ad)

Obama’s 2024 Confession

Barack Obama’s confession about the 2024 election just leaked online… In short, he’s worried Biden “could very well lose.” But before you think that means Trump will win… You should see the evidence I’ve found about an election shock that could come as soon as August 19th.

February 10, 2024 | americanbankingnews.com

Qiagen to Post Q1 2024 Earnings of $0.43 Per Share, William Blair Forecasts (NYSE:QGEN)

February 9, 2024 | americanbankingnews.com

Qiagen (NYSE:QGEN) Given New $60.00 Price Target at Citigroup

February 9, 2024 | markets.businessinsider.com

Buy Recommendation for Qiagen: Anticipated Growth and Strategic Underpromise

February 9, 2024 | finance.yahoo.com

The Qiagen N.V. (NYSE:QGEN) Full-Year Results Are Out And Analysts Have Published New Forecasts

February 8, 2024 | markets.businessinsider.com

Maintaining Buy on Qiagen: Strong Q4 Performance and Positive Long-Term Outlook

February 12, 2024 | The Freeport Society (Ad)

New Trump Bombshell

I believe Donald J. Trump will go down as America’s last Republican president. But NOT for the reasons you may think… If I’m right, the soul of this country will change forever…

February 8, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Qiagen (QGEN) and Ascendis Pharma (ASND)

February 7, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), Qiagen (QGEN) and Inspire Medical Systems (INSP)

February 7, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Qiagen (QGEN), Inspire Medical Systems (INSP) and Gilead Sciences (GILD)

February 7, 2024 | finance.yahoo.com

QIAGEN (QGEN) Q4 Earnings Miss, Operating Margin Expands

February 6, 2024 | finance.yahoo.com

Qiagen (QGEN) Reports Q4 Earnings: What Key Metrics Have to Say

February 6, 2024 | markets.businessinsider.com

QIAGEN exceeds outlook for Q4 2023, led by 8% CER sales growth in non-COVID products and improved operational profitability

February 6, 2024 | msn.com

Qiagen gains amid report potential buyer lining up advisors, financing

February 6, 2024 | msn.com

Stock Index Futures Tick Lower as Investors Await More Corporate Earnings and Fed Speak

February 5, 2024 | msn.com

Qiagen Q4 2023 Earnings Preview

January 31, 2024 | realmoney.thestreet.com

Qiagen price target lowered by EUR 1.45 at Morgan Stanley

January 26, 2024 | markets.businessinsider.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (OtherSNYNF) and Qiagen (QGEN)

January 25, 2024 | finanznachrichten.de

QIAGEN N.V.: QIAGEN announces partnership with Penn State University to advance microbiome sciences

January 25, 2024 | markets.businessinsider.com

Qiagen Collaborates With Penn State University To Create Research & Educational Facility

January 25, 2024 | finance.yahoo.com

QIAGEN announces partnership with Penn State University to advance microbiome sciences

January 19, 2024 | finanznachrichten.de

QIAGEN N.V.: QIAGEN announces details for completion of synthetic share repurchase of up to approximately $300 million

January 18, 2024 | msn.com

Qiagen announces details of synthetic share repurchase plan of up to $300M

January 18, 2024 | finance.yahoo.com

QIAGEN announces details for completion of synthetic share repurchase of up to approximately $300 million

January 15, 2024 | finance.yahoo.com

Those who invested in Qiagen (NYSE:QGEN) five years ago are up 22%

See More Headlines

Receive QGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Qiagen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 1/30 Dividend: 1/30/2024
Dividend Payable: 1/30/2024
Last Earnings: 2/06/2024
Today: 2/12/2024
Next Earnings (Estimated): 5/01/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NYSE:QGEN
CUSIP: N/A
CIK: 1015820
Web: www.qiagen.com
Phone: (177) 355-6600
Fax: 31-77-355-6658
Employees: 6,178
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $51.79
High Stock Price Target: $60.00
Low Stock Price Target: $43.30
Potential Upside/Downside: +16.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.63
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): $1.5128
Trailing P/E Ratio: 29.41
Forward P/E Ratio: 21.19
P/E Growth: 16.37
Net Income: $423.21 million
Net Margins: 17.37%
Pretax Margin: 21.33%
Return on Equity: 13.15%
Return on Assets: 7.72%

Debt

Debt-to-Equity Ratio: 0.37
Current Ratio: 3.74
Quick Ratio: 2.98

Sales & Book Value

Annual Sales: $1.97 billion
Price / Sales: 5.01
Cash Flow: $3.57 per share
Price / Cash Flow: 12.45
Book Value: $15.69 per share
Price / Book: 2.84

Miscellaneous

Outstanding Shares: 221,160,000
Free Float: 201,256,000
Market Cap: $9.84 billion
Optionable: Optionable
Beta: 0.43

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for February 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Thierry Bernard (Age 58)
CEO, MD & Member of Management Board
Comp: $2.67M
Dr. Roland Sackers (Age 55)
CFO, MD & Member of Management Board
Comp: $1.33M
Mr. Antonio Santos
Senior VP & Head of Global Operations
Mr. John Gilardi
Vice President of Corporate Communications & Investor Relations
Ms. Stephany Foster (Age 45)
Senior VP & Head of Human Resources
Dr. Thomas Schweins
Senior Vice President of Life Science Business Area
Dr. Thomas Theuringer
Senior Director & Head of External Communications
Mr. Jean-Pascal Viola
Senior VP & Head of Molecular Diagnostics Business Area
Dr. Jonathan G. Sheldon Ph.D. (Age 52)
Senior Vice President of Qiagen Digital Insights Business Area
Mr. Thomas Neidert
Vice President of Global Treasury

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

QGEN Stock Analysis - Frequently Asked Questions

Should I buy or sell Qiagen stock right now?: 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Qiagen in the last twelve months. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" QGEN shares.
View QGEN analyst ratings or view top-rated stocks.
What is Qiagen's stock price target for 2024?: 8 brokerages have issued 12 month price objectives for Qiagen's shares. Their QGEN share price targets range from $43.30 to $60.00. On average, they anticipate the company's stock price to reach $51.79 in the next year. This suggests a possible upside of 16.4% from the stock's current price.
View analysts price targets for QGEN or view top-rated stocks among Wall Street analysts.
How have QGEN shares performed in 2024?: Qiagen's stock was trading at $44.7732 at the beginning of the year. Since then, QGEN stock has decreased by 0.6% and is now trading at $44.49.
View the best growth stocks for 2024 here.
Are investors shorting Qiagen?: Qiagen saw a increase in short interest in the month of January. As of January 15th, there was short interest totaling 3,120,000 shares, an increase of 28.9% from the December 31st total of 2,420,000 shares. Based on an average daily trading volume, of 1,370,000 shares, the days-to-cover ratio is presently 2.3 days. Approximately 1.4% of the company's shares are sold short.
View Qiagen's Short Interest.
When is Qiagen's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our QGEN earnings forecast.
How were Qiagen's earnings last quarter?: Qiagen (NYSE:QGEN) released its quarterly earnings results on Tuesday, February, 6th. The company reported $0.55 earnings per share for the quarter, hitting the consensus estimate of $0.55. The firm had revenue of $509 million for the quarter, compared to analyst estimates of $500.77 million. Qiagen had a net margin of 17.37% and a trailing twelve-month return on equity of 12.99%. During the same period in the prior year, the company earned $0.53 EPS.
How often does Qiagen pay dividends? What is the dividend yield for Qiagen?: Qiagen announced a -- dividend on Monday, January 22nd. Investors of record on Wednesday, January 31st will be paid a dividend of $1.3196 per share on Tuesday, January 30th. The ex-dividend date of this dividend is Tuesday, January 30th.
Read our dividend analysis for QGEN.
What ETFs hold Qiagen's stock?: ETFs with the largest weight of Qiagen (NYSE:QGEN) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), First Trust NYSE Arca Biotechnology Index Fund (FBT), Newday Ocean Health ETF (AHOY), VanEck Biotech ETF (BBH), Franklin Genomic Advancements ETF (HELX), WisdomTree U.S. AI Enhanced Value Fund (AIVL) and ROBO Global Healthcare Technology and Innovation ETF (HTEC).

When did Qiagen's stock split?: Qiagen's stock reverse split on Tuesday, January 30th 2024. The 24.25-25 reverse split was announced on Tuesday, January 30th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 30th 2024. An investor that had 100 shares of stock prior to the reverse split would have 97 shares after the split.
What guidance has Qiagen issued on next quarter's earnings?: Qiagen updated its FY 2024 earnings guidance on Tuesday, February, 6th. The company provided earnings per share (EPS) guidance of 2.100- for the period, compared to the consensus EPS estimate of 2.100. The company issued revenue guidance of $2.0 billion-, compared to the consensus revenue estimate of $2.1 billion.
What is Thierry Bernard's approval rating as Qiagen's CEO?: 33 employees have rated Qiagen Chief Executive Officer Thierry Bernard on Glassdoor.com. Thierry Bernard has an approval rating of 65% among the company's employees.
What other stocks do shareholders of Qiagen own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Qiagen investors own include NVIDIA (NVDA), QUALCOMM (QCOM), Gilead Sciences (GILD), Advanced Micro Devices (AMD), PayPal (PYPL), Netflix (NFLX), Pfizer (PFE), Cisco Systems (CSCO), Amgen (AMGN) and Lam Research (LRCX).
Who are Qiagen's major shareholders?: Qiagen's stock is owned by many different institutional and retail investors. Top institutional shareholders include Massachusetts Financial Services Co. MA (10.88%), Norges Bank (2.75%), DekaBank Deutsche Girozentrale (1.41%), BNP Paribas Financial Markets (0.69%), Neuberger Berman Group LLC (0.65%) and Allspring Global Investments Holdings LLC (0.59%).
How do I buy shares of Qiagen?: Shares of QGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:QGEN) was last updated on 2/12/2024 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial